ADOPTION II: NBI Versus White Light Endoscopy for Optical Characterization of Neoplastic Polyps in the Colorectum

Sponsor
Technische Universität München (Other)
Overall Status
Unknown status
CT.gov ID
NCT03679429
Collaborator
(none)
370
3
20
123.3
6.2

Study Details

Study Description

Brief Summary

Adenomas, serrated adenomas and hyperplastic polyps are polypoid lesion in the colorectum. At the present moment, all polyps should be resected endoscopically, although only adenomas and serrated adenomas, but not hyperplastic polyps have the potential to develop colorectal cancer. This approach enables the conduction of microscopic investigations of the lesions. By today, only the pathological diagnosis can distinguish exactly between these three polyp entities. Some studies have investigated the value of the optical characterization approach which is based on visual assessment of the polyp' surface structures. Based upon optical polyp features users are encouraged to predict histopathological polyp diagnoses solely on behalf of optical or endoscopical criteria. This method is conducted in real time during colonoscopy. If it could be shown, that endoscopist using the optical characterization approach are able to predict histopathological diagnoses of colonic polyps sufficiently this would possibly lead to simplification of diagnostic procedures. For instance, it would be conceivable to resect small polyps and discard them without further assessment by a pathologist. One problem in this context is a correct differentiation between hyperplastic polyps and serrated adenomas. These two polyp entities are known to show similar optical features. However, while serrated adenomas are premalignant lesions hyperplastic polyps have benign histology and never develop into cancer. It is therefore important to sufficiently distinguish hyperplastic polyps from serrated lesions.

In this study we want to investigate whether the use of narrow-band imaging (NBI) would be capable to rise accuracy of optical polyp predictions compared to standard HD white light endoscopy. NBI is a light filter tool which can be activated by pressing a button at the endoscope. The use of NBI leads to an endoscopic picture which appears blue and enables endoscopists to better assess surface structures and vascular patterns.

In a prospective randomised multicenter setting we plan to conduct colonoscopy in 370 patients. Half of the patients will be examined without the use of NBI (control arm). In these cases colonoscopists will assess optical diagnosis of polyps without turning on the NBI tool. If polyps are detected in patients belonging to the intervention arm NBI will be used and optical diagnosis will be determined using the WASP (Workgroup serrAted polypS and Polyposis) classification. All polyps will be resected and send to pathology for further microscopic assessment. After completing the trial we aim to compare accuracy of the optical diagnosis in both groups. Our hypothesis is, that by using NBI accordance between optical and histopathological diagnosis can be increased from 80% to 90%.

Condition or Disease Intervention/Treatment Phase
  • Device: NBI Function

Study Design

Study Type:
Observational
Anticipated Enrollment :
370 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
NBI Versus White Light Endoscopy for Optical Characterization of Neoplastic Polyps in the Colorectum - the ADOPTION II Study
Anticipated Study Start Date :
Nov 1, 2018
Anticipated Primary Completion Date :
May 1, 2020
Anticipated Study Completion Date :
Jul 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Control group

Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITHOUT using the NBI function of the scope.

Intervention

Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined by using the NBI function of the scope.

Device: NBI Function
In the intervention arm polyps will be optically characterized using the NBI function. The WASP (Workgroup serrAted polypS and Polyposis) classification will be used in order to determine the optical diagnosis.
Other Names:
  • NBI Function integrated in the CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope
  • Outcome Measures

    Primary Outcome Measures

    1. Accuracy optical biopsy [up to 2 weeks (participants will be followed for the duration of hospital stay or outpatient treatment, an expected average of 2 weeks)]

      After obtaining the histopathological diagnosis of resected polyps (approximately 3 days - 2 weeks after colonoscopy ) accuracy of optical diagnosis can be determined

    Secondary Outcome Measures

    1. Adenoma detection rate [up to 2 weeks (participants will be followed for the duration of hospital stay or outpatient treatment, an expected average of 2 weeks)]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • medical indication for colonoscopy

    • age ≥ 40 years

    • written consent given by patient

    Exclusion Criteria:
    • age < 40 years

    • patients denying written consent

    • pregnant women

    • ASA class IV, V and VI

    • known contraindication for polyp resection

    • indication for colonoscopy: preknown adenoma/polyp/carcinoma or inflammatory bowel disease

    • indication for colonoscopy: emergency (e.g. severe rectal bleeding)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Klinik für Innere Medizin II am Klinikum rechts der Isar der Technischen Universität München Munich Bayern Germany 81677
    2 Universitätsklinikum Erlangen, Medizinische Klinik 1 Erlangen Germany 91054
    3 Robert-Bosch-Krankenhaus Stuttgart Germany 70376

    Sponsors and Collaborators

    • Technische Universität München

    Investigators

    • Principal Investigator: Peter Klare, MD, Klinikum rechts der Isar der Technischen Universität München
    • Study Director: Roland M Schmid, Professor, Klinikum rechts der Isar der Technischen Universität München
    • Study Chair: Timo Rath, Professor, Universitätsklinikum Erlangen
    • Study Chair: Jan Peveling-Oberhag, MD, Robert Bosch-Krankenhaus Stuttgart

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Peter Klare, Dr. med. Peter Klare, Technische Universität München
    ClinicalTrials.gov Identifier:
    NCT03679429
    Other Study ID Numbers:
    • ADOPTION II
    First Posted:
    Sep 20, 2018
    Last Update Posted:
    Sep 20, 2018
    Last Verified:
    Sep 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Peter Klare, Dr. med. Peter Klare, Technische Universität München
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 20, 2018